oxybutynin chloride

( ox-i-byoo’ti-nin )
Ditropan, oxbutynin, oxytrol transdermal

neurogenic bladder, overactive bladder. amantadine: increased anticholiner-

Pharmacologic class: synthetic tertiary gic effects. atenolol: increased levels of
amine. Therapeutic class: anticholinergic. atenolol. digoxin: increased levels of dig.
Pregnancy risk category: B. INDICATIONS & DOSAGE haloperidol: decreased levels of haloperi-
adult PO.: 5mg bid-tid, not to exceed 5mg dol. levodopa: decreased levels of lev-
qid, XR tabs 5mg/day may increase by odopa. nitrofurantoin:increased levels of
HOW SUPPLIED 5mg, max 30mg/day. nitrofurantoin. nitrofurantoin: increased
syr: 5mg/5ml. adult transdermal.: apply one patch levels of nitrofurantoin. antihistamines:
tabs: 5 mg. to abdomen, hip, buttock 2 x wk (q3-4 increased anticholinergic effects.
ext rel tabs: 5, 10, 15mg. days).
transdermal : 3.9 mg/day. geriatric PO.: 2.5-5mg tid, increase by CONTRAINDICATIONS & PRECAU-
2.5mg q several days. TIONS
PHARMACOKINETICS ■ hypersensitivity, GI obstruction, GU ob-
ADVERSE REACTIONS struction, glaucoma, severe colitis, myas-
Absorption: rapidly absorbed. Distribu-
thenia gravis, unstable CV.
tion: unknown. Metabolism: liver. Excre- CNS: anxiety, restlessness, dizziness, ■ breastfeeding, children under 12, geri-
tion: unknown. SEIZURES. CV: palpitations, sinus tachy- atric, suspected glaucoma.
cardia, peripheral edema, HTN. EENT:
Route Onset Peak Duration
PO 1/2-1hr 3-4 hr 6-10 hr
blurred vision, increased intraocular ten-
sion, dry mouth, throat. GI: nausea, vom-
iting, anorexia, pain, constipation. GU: dy-
suria, impotence, retention.
PHARMACODYNAMICS
relaxes smooth muscles in urinary tract by INTERACTIONS
inhibiting acetylcholine at postganglion- acetaminophen: decreased levels of ac-
ic sites, decreased symptoms of urgency, etaminophen. phenothiazines: increased
nocturia, incontinenc, antispasmodic for or decreased levels of phenothiazines.
 in the geriatric.
Evaluation

Assessment ■ Absenc of dysuria, frequency, noctura,

and incontinence.
■ Assess for allergic reactions, rash, ur-
ticaria, if these occur, product should be
discontinued. Assess urinary patterns, dis-
tention, nocturia, frequency, urgency, in-
continence, cathetrization may be required
to remove residual urine.
Nursing Diagnosis

■ Knowledge, deficient (teaching).

■ Pain, acute (uses).
■ Urinary elimination, impaired (uses).
Planning & Implementation

■Do not break, crush, or chew XR tabs.

May be given with meals or fluids or on an
empty stomach.
Patient Teaching

■ Avoid hazardous activities until response

is known, dizziness, blurred vision may oc-
cur. Avoid OTC meds with alcohol or oth-
er CNS depressant. Prevent photophobia
by wearing sunglasses. Frequent rinsing of
mouth, sips of water for dry mouth. Stay
cool, avoid hot weather, strenous activity
since overheating may occur, product de-
creases perspiration. Report CNS effects,
confusion, anxiety, anticholinergic effect